WHO adds first molecular diagnostic test for Bundibugyo virus to Emergency Use Listing as largest recorded outbreak continues spreading across DRC and Uganda.
By Adam Makins · 
The World Health Organization has taken a significant step in combating one of Africa’s most dangerous viral threats. Today, WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL), a move that could reshape how quickly and accurately health systems identify infected patients during this critical outbreak.
Bundibugyo virus is no minor concern. It’s one of three Ebola virus species known to trigger large-scale human outbreaks, and right now, it’s spreading across the Democratic Republic of the Congo with alarming speed. As of today, 1,406 laboratory-confirmed cases and 438 deaths have been reported in DRC alone, making this the largest recorded outbreak of BDBV ever documented.
The urgency here cannot be overstated. When WHO Director-General Dr Tedros Adhanom Ghebreyesus declared a public health emergency of international concern on May 17, 2026, the diagnostic infrastructure was woefully inadequate. Testing capacity was concentrated at just two main sites: Institut National de Recherche Biomédicale in Kinshasa and Goma, with a combined daily capacity of only 200 to 400 tests.
That bottleneck was literally a death sentence for patients waiting days for confirmation. Early diagnosis isn’t just a matter of statistics. It determines whether patients get treatment in time, whether contacts can be traced, and whether an outbreak spirals into total chaos or gets contained.
The response has been substantial. With support from WHO and the Africa Centres for Disease Control and Prevention, testing capacity has expanded to a network of 10 laboratories across affected provinces, now reporting over 2,000 tests per day. But capacity means nothing without reliable diagnostics. That’s why this EUL approval matters so profoundly.
The newly approved diagnostic detects BDBV by identifying its genetic material directly in blood samples. This molecular approach offers both speed and accuracy, two qualities that are non-negotiable during a fast-moving outbreak. The test works by pinpointing the virus’s genetic fingerprint, leaving little room for false negatives or dangerous false positives that could undermine contact tracing efforts.
WHO’s Emergency Use Listing procedure isn’t a rubber stamp. The organization rigorously assesses quality, safety, and performance of health products against minimum international standards. This approval signals that the test has cleared that bar during an actual emergency, not just in controlled laboratory conditions.
This single approval is just the opening move. WHO has launched additional calls for manufacturers and is currently reviewing more applications for BDBV diagnostics. Simultaneously, WHO and Africa CDC are establishing a joint validation platform with partners like PATH, FIND, and CHAI to rapidly evaluate other diagnostic candidates, including near-point-of-care molecular tests and antigen rapid diagnostic tests.
This layered approach is smart. Point-of-care tests could eventually allow health workers to diagnose BDBV in remote clinics without waiting for results from centralized laboratories. That capability could be transformative for early case detection and contact management in the DRC’s difficult geography.
What’s happening with Bundibugyo virus diagnosis reflects a fundamental principle in modern public health emergency response: speed plus certainty saves lives. Countries facing outbreaks need to make procurement decisions quickly, but they also need confidence that the tools they’re purchasing actually work in the messy, unpredictable conditions of a real crisis.
The EUL mechanism serves that dual purpose. It accelerates access while maintaining standards. It helps UN procurement agencies and governments navigate complex decisions under extreme time pressure.
As this outbreak continues to expand, every diagnostic test deployed represents both an opportunity to identify a case early and a chance to prevent further transmission. The question isn’t whether WHO’s approval of this first test will matter. It’s whether enough additional diagnostics will follow quickly enough.
Source: World Health Organization
